RxDoctor Payments Data

Aaron Young, MD

Family Medicine · Elkhart, INNPI 1750504734

Payments from drug & device makers

$6,123in general payments, 2019–2025

Across 429 payments — averaging $14.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$862
  • AbbVie$830
  • Lilly USA, LLC$633
  • AstraZeneca$368
  • Merck$343
  • Boehringer Ingelheim$292
  • plus $3K from 42 others

What the payments were for

  • Speaking & faculty fees$601%
  • Food & beverage$6,01798%
  • Education$461%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,123 in reported general payments places this provider in the 85th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$200,382
Medicare patients
305
Services billed
9,541

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin98$135,055
OzempicSemaglutide72$108,842
TrulicityDulaglutide52$77,072
MounjaroTirzepatide29$43,240
EliquisApixaban41$43,142
FarxigaDapagliflozin Propanediol38$38,803
WegovySemaglutide23$35,715
Janumet XrSitagliptin Phos/Metformin Hcl14$20,208
Synjardy XrEmpagliflozin/Metformin Hcl14$19,170
Tresiba Flextouch U-200Insulin Degludec19$15,935
EntrestoSacubitril/Valsartan11$15,534
Stiolto RespimatTiotropium Br/Olodaterol Hcl12$14,557
Breo ElliptaFluticasone/Vilanterol27$12,916
Breztri AerosphereBudesonide/Glycopyr/Formoterol18$11,411
GlyxambiEmpagliflozin/Linagliptin14$10,821

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy Xr, Stiolto Respimat, Glyxambi$292$179,604138 claims
Novo NordiskOzempic, Wegovy$862$144,55895 claims
Lilly USA, LLCTrulicity, Mounjaro$633$120,31281 claims
AstraZenecaFarxiga, Breztri Aerosphere$368$50,21456 claims
PfizerEliquis, Premarin$248$45,56552 claims
GSKBreo Ellipta, Trelegy Ellipta, Arexvy, Shingrix$98$30,23271 claims
MerckJanumet Xr$343$20,20814 claims
NovartisEntresto$241$15,53411 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$96$5,46011 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$25$2,918379 claims
AbbVieSynthroid$830$2,62141 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Elkhart

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →